- Home
- RUN vs PRAX Comparison
RUN vs PRAX Comparison
Compare RUN & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RUN
- PRAX
- Stock Information
- Founded
- RUN 2007
- PRAX 2015
- Country
- RUN United States
- PRAX United States
- Employees
- RUN N/A
- PRAX N/A
- Industry
- RUN Industrial Machinery/Components
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- RUN Miscellaneous
- PRAX Health Care
- Exchange
- RUN Nasdaq
- PRAX Nasdaq
- Market Cap
- RUN 4.4B
- PRAX 4.0B
- IPO Year
- RUN 2015
- PRAX 2020
- Fundamental
- Price
- RUN $18.50
- PRAX $171.51
- Analyst Decision
- RUN Buy
- PRAX Strong Buy
- Analyst Count
- RUN 18
- PRAX 13
- Target Price
- RUN $20.00
- PRAX $228.69
- AVG Volume (30 Days)
- RUN 9.7M
- PRAX 863.5K
- Earning Date
- RUN 11-06-2025
- PRAX 11-05-2025
- Dividend Yield
- RUN N/A
- PRAX N/A
- EPS Growth
- RUN N/A
- PRAX N/A
- EPS
- RUN N/A
- PRAX N/A
- Revenue
- RUN $2,316,656,000.00
- PRAX $7,463,000.00
- Revenue This Year
- RUN $11.35
- PRAX N/A
- Revenue Next Year
- RUN $9.26
- PRAX $44.43
- P/E Ratio
- RUN N/A
- PRAX N/A
- Revenue Growth
- RUN 13.79
- PRAX 364.98
- 52 Week Low
- RUN $5.38
- PRAX $26.70
- 52 Week High
- RUN $22.44
- PRAX $206.71
- Technical
- Relative Strength Index (RSI)
- RUN 47.14
- PRAX 53.15
- Support Level
- RUN $16.89
- PRAX $160.11
- Resistance Level
- RUN $20.99
- PRAX $197.50
- Average True Range (ATR)
- RUN 1.70
- PRAX 14.95
- MACD
- RUN -0.18
- PRAX -5.68
- Stochastic Oscillator
- RUN 46.13
- PRAX 37.60
About RUN Sunrun Inc.
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.